Diffuse large B-cell lymphoma

IMV Inc. Presents Positive Initial Results From The MVP-S Phase 2B VITALIZE Trial

Retrieved on: 
Monday, February 13, 2023
Biotechnology, Health, General Health, Healthcare Reform, Pharmaceutical, Oncology, Other Science, Research, Public Policy, Government, Science, Clinical Trials, Ovarian cancer, IMV, TSX, Patient, Pembrolizumab, Hematological Cancer Research Investment and Education Act, ECOG, DPX, Diffuse large B-cell lymphoma, Platinum, Pharmaceutical industry, Medical imaging

Key initial findings from the ongoing VITALIZE trial:

Key Points: 
  • Key initial findings from the ongoing VITALIZE trial:
    8 Patients with an ECOG1 score of 0-1 have been enrolled in arm 1 of the study.
  • Overall Response Rate (“ORR”) will be communicated when the totality of stage one data are available for definitive assessment.
  • “VITALIZE is our most advanced and rigorous trial to date, and we are encouraged by the way the data for MVP-S are trending.
  • This is the most refractory population of patients we have treated so far, and to show complete, confirmed clinical responses is notable.

Eurofins Viracor Launches Ground-Breaking Test for Assessing Expansion and Persistence of CAR-T Therapy in Cancer Patients

Retrieved on: 
Thursday, February 16, 2023
Infection, Cancer, Research, Allergy, Diffuse large B-cell lymphoma, Patient, Immunotherapy, Vaccine, Pharmaceutical industry

LENEXA, Kan., Feb. 16, 2023 /PRNewswire/ -- Eurofins Viracor LLC, a leader in testing for infectious disease, immunology, and allergy, today announced the launch of a ground-breaking test that can assess the expansion and persistence of Chimeric Antigen Receptor T-Cell (CAR-T) therapy in patients with pre-B cell acute lymphoblastic leukemia and B cell lymphomas.

Key Points: 
  • The test, based on a method developed by Eurofins Viracor, is designed to help clinicians better understand how CAR-T therapy is performing for their patients.
  • CAR-T therapy is a revolutionary form of immunotherapy that uses genetically engineered T-cells to attack cancer cells and has shown promising results in treating a variety of cancers.
  • Research has demonstrated that the persistence and expansion of CAR-T therapy are important indicators of how long the therapy is likely to remain effective in the patient.
  • The launch of this test marks an important step forward in the evaluation and management of CAR-T therapy in cancer patients.

IMV Inc. Announces Update and Planned 2023 Milestones to Advance Clinical Development of its Lead Therapeutic, MVP-S

Retrieved on: 
Sunday, January 8, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Cancer, Smith College, Pembrolizumab, Diffuse large B-cell lymphoma, DPX, Sanofi, TSX, SITC, IMV, AACR, DLBCL, Ovarian cancer, MBA, Risk, Growth, Patient, Biochemistry, Harvard Business School, Bristol Myers Squibb, Hematology, Hematological Cancer Research Investment and Education Act, Prevent Cancer Foundation, Medical device, Pharmaceutical industry, Management, Economics

IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today outlined its planned 2023 milestones to advance the clinical development of its lead therapeutic, maveropepimut-S (MVP-S).

Key Points: 
  • IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today outlined its planned 2023 milestones to advance the clinical development of its lead therapeutic, maveropepimut-S (MVP-S).
  • “We made significant changes at IMV in 2022 to build the proper foundation for success in 2023.
  • Complete responses were observed in patients who received at least three previous lines of treatment, including CAR-T's.
  • Michael Bailey, Board Chairman of IMV, commented: “We are exceptionally grateful for Julia’s service and her significant contributions to IMV over many years.

ADC Therapeutics Appoints Jose Carmona as Chief Financial Officer

Retrieved on: 
Monday, December 19, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Rubius, CFO, PBD, El Rubius, Stock dilution, Patient, NYSE, B-cell lymphoma, Control, Lymphatic system, Novartis, Partnership, Growth, ADC, FDA, Multimedia, Information technology, Therapy, Diffuse large B-cell lymphoma, Hotspot, Cancer, Management, Fine chemical, San Francisco Bay Area

ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of Jose “Pepe” Carmona as Chief Financial Officer (CFO), effective December 19, 2022.

Key Points: 
  • ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of Jose “Pepe” Carmona as Chief Financial Officer (CFO), effective December 19, 2022.
  • As we enter the next phase of growth, I am confident that his extensive financial background, deep capital markets experience and proven leadership in the pharmaceutical industry will help drive our corporate objectives and deliver long-term value for shareholders,” said Ameet Mallik, Chief Executive Officer of ADC Therapeutics.
  • He most recently served as CFO of Rubius Therapeutics where he was responsible for all financial functions as well as business development, investor relations, information technology and procurement.
  • “I am thrilled to join ADC Therapeutics, especially at this exciting point in the Company’s evolution,” said Mr. Carmona.

Zynlonta® (loncastuximab tesirine) approved in the EU for the treatment of relapsed or refractory diffuse large B-cell lymphoma

Retrieved on: 
Wednesday, December 21, 2022
NYSE, Food, Malignancy, Disease, PMC, Safety, EMA, PBD, US Foods, Patient, Research and development, Nasdaq Stockholm, B-cell lymphoma, Lymphoma, Marketing, Lymphoid leukemia, FDA, Diffuse large B-cell lymphoma, Development, EC, SEK, Genetics, Committee, Control, Lymphatic system, Cancer research, ADC, Enzyme, DNA, Therapy, Degenerative disease, Incidence, Distortion, Cancer, Cancer Research UK, European Commission, Induced cell cycle arrest, USD, European Commission–AstraZeneca COVID-19 vaccine dispute, DNA repair, Medical Affairs Bureau, Pharmaceutical industry, Fine chemical, San Francisco Bay Area, DLBCL, Swedish Orphan Biovitrum, EU, Loncastuximab tesirine

"We are thrilled that Zynlonta will be available to help fill a critical unmet need for patients with DLBCL across Europe."

Key Points: 
  • "We are thrilled that Zynlonta will be available to help fill a critical unmet need for patients with DLBCL across Europe."
  • Diffuse large B-cell lymphoma (DLBCL) is an aggressive and malignant disease in haematology with an incidence in Europe of approximately 8.8 cases per 100,000 adults per year1.
  • ADC Therapeutics' CD19-directed ADC Zynlonta (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy.
  • Postal address SE-112 76 Stockholm, Sweden
    For details on how to contact the Sobi Investor Relations Team, please click here .

IMV Inc. Announces Initial Data from the Ongoing Phase 2B VITALIZE Trial in Patients with r/r DLBCL

Retrieved on: 
Thursday, December 15, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Immunotherapy, ASCT, Diffuse large B-cell lymphoma, Partial, Hematological Cancer Research Investment and Education Act, IMV, Rutgers Cancer Institute of New Jersey, CD8, Endpoint security, Survivin, Pembrolizumab, CD4, ORR, SEDAR, Cancer, RWJBarnabas Health, TSX, DPX, Immune system, Cyclophosphamide, Bladder cancer, Degenerative disease, Patient, EDGAR, PD-L1, Pharmaceutical industry, Medical imaging, DLBCL

He added: We find it remarkable that we have seen complete responses in this trial in patients that were refractory to prior cellular therapy and other advanced therapies.

Key Points: 
  • He added: We find it remarkable that we have seen complete responses in this trial in patients that were refractory to prior cellular therapy and other advanced therapies.
  • Clinical activity in a highly refractory patient population may represent a path to registration in DLBCL.
  • The VITALIZE Phase 2B trial is a randomized, parallel group, Simon two-stage study designed to assess IMVs lead candidate, MVP-S, in combination with pembrolizumab with or without cyclophosphamide.
  • A Phase 1 clinical trial in bladder cancer, using MVP-S or DPX-SurMAGE, was initiated in early 2022.

FREENOME PRESENTS RESEARCH HIGHLIGHTING THE PROMISE OF IDENTIFYING DRUG-RESPONSE BIOMARKERS FOR DLBCL PATIENTS

Retrieved on: 
Monday, December 12, 2022
Heme, Therapy, DLBCL, Lymphatic system, Immune system, PBD, Society, Biomarker, Patient, Cancer, ADC, Research, Biology, NYSE, Diffuse large B-cell lymphoma, FDA, Molecular biology, Nucleic acid thermodynamics, Multimedia, Loncastuximab tesirine, Control, SAN, Blood, Machine learning, ASH, Hodgkin lymphoma, Medical imaging, Fine chemical, Pharmaceutical industry, San Francisco Bay Area, Catriona lonca, Camisole

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2022 /PRNewswire/ -- Freenome, a privately held biotech company, presented research on Saturday at the American Society of Hematology (ASH) Annual Meeting in New Orleans.

Key Points: 
  • The findings presented at ASH show promise in identifying biomarkers associated with response to lonca and also suggested mechanisms of resistance seen in non-responders, which may inform future drug combination research.
  • "We look forward to further exploration of these findings to determine their significance for healthcare providers trying to identify the most appropriate treatments for patients with DLBCL."
  • "ADC Therapeutics is a leader in the field of antibody-drug conjugates," said Mike Nolan , chief executive officer, Freenome.
  • The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

Biocytogen Enters into Antibody Agreement with ADC Therapeutics

Retrieved on: 
Monday, November 28, 2022
Research, Infectious Diseases, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, Doctor of Philosophy, ADC, Control, Antibody, Diffuse large B-cell lymphoma, Multinational corporation, Therapy, Patient, Medication, Neoplasm, Lymphatic system, HKEX, NYSE, Cancer, PBD, Research, Area studies, FDA, Fine chemical, San Francisco Bay Area

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that it has entered into an evaluation and option agreement with ADC Therapeutics SA.

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that it has entered into an evaluation and option agreement with ADC Therapeutics SA.
  • Under the agreement, Biocytogen will provide ADC Therapeutics with monoclonal and/or biparatopic antibodies directed against three tumor targets, generated through Biocytogens Project Integrum (also called RenMiceTM HiTS Platform ).
  • ADC Therapeutics will carry out feasibility studies and be responsible for further development and commercialization of the ADC products if the company exercises an option.
  • We believe this collaboration with ADC Therapeutics will underscore the value of Biocytogens proprietary antibody discovery and screening platforms, said Dr. Yuelei Shen, President and CEO of Biocytogen.

Biocytogen Enters into Antibody Agreement with ADC Therapeutics

Retrieved on: 
Monday, November 28, 2022
Biotechnology, Health, Science, Pharmaceutical, Research, Doctor of Philosophy, ADC, Control, Antibody, Diffuse large B-cell lymphoma, Multinational corporation, Therapy, Patient, Medication, Neoplasm, Lymphatic system, HKEX, NYSE, Cancer, PBD, Research, Area studies, FDA, Fine chemical, San Francisco Bay Area

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that it has entered into an evaluation and option agreement with ADC Therapeutics SA.

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that it has entered into an evaluation and option agreement with ADC Therapeutics SA.
  • Under the agreement, Biocytogen will provide ADC Therapeutics with monoclonal and/or biparatopic antibodies directed against three tumor targets, generated through Biocytogens Project Integrum (also called RenMiceTM HiTS Platform).
  • ADC Therapeutics will carry out feasibility studies and be responsible for further development and commercialization of the ADC products if the company exercises an option.
  • We believe this collaboration with ADC Therapeutics will underscore the value of Biocytogens proprietary antibody discovery and screening platforms, said Dr. Yuelei Shen, President and CEO of Biocytogen.

ADC Therapeutics to Participate in the Jefferies London Healthcare Conference

Retrieved on: 
Monday, November 7, 2022
Oncology, Health, FDA, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Company, Lymphatic system, ADC, Hodgkin lymphoma, FDA, Investor, NYSE, Webcast, Conference, B-cell lymphoma, Therapy, Event, PBD, Diffuse large B-cell lymphoma, View, Technology, Control, Patient, Cancer, Fine chemical, San Francisco Bay Area, Camisole

ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15th at 9:45 a.m. GMT.

Key Points: 
  • ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15th at 9:45 a.m. GMT.
  • A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics website, ir.adctherapeutics.com .
  • ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs).
  • ADC Therapeutics is based in Lausanne (Biople), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey.